For: | Di Dato F, Iorio R. Expanding indications for chronic hepatitis B treatment: Is it really desirable to treat everyone? World J Gastroenterol 2024; 30(17): 2294-2297 [PMID: 38813053 DOI: 10.3748/wjg.v30.i17.2294] |
---|---|
URL: | https://www.wjgnet.com/1948-5182/full/v30/i17/2294.htm |
Number | Citing Articles |
1 |
Chari Cohen, Thomas Tu, Philippa C Matthews, Su Wang, Jessica Hicks, Manal H El-Sayed, John E Tavis. Patient and public health perspectives to inform expansion of hepatitis B treatment guidelines. The Lancet Gastroenterology & Hepatology 2025; doi: 10.1016/S2468-1253(25)00052-4
|
2 |
Yupeng Wang, Shuangxing Li, Tianqi Ren, Yikun Zhang, Bo Li, Xingchao Geng. Mechanism of emodin in treating hepatitis B virus-associated hepatocellular carcinoma: network pharmacology and cell experiments. Frontiers in Cellular and Infection Microbiology 2024; 14 doi: 10.3389/fcimb.2024.1458913
|
3 |
Yongbin Wu, Guifang Tang, Jian Wen, Ying Wan, Yufei Wang, Ling Li. Serum hepatitis B virus RNA in low-level viremia of chronic hepatitis B: clinical features and association with virological response. Virology Journal 2025; 22(1) doi: 10.1186/s12985-025-02712-y
|